Radiotherapy for Keloids

Keloid Clinical Trial

Official title: Primary Radiotherapy for the Treatment of Keloids: A Pilot Study

Status Active, not recruiting

Clinical Trial Summary

The purpose of this pilot study is to evaluate the safety and efficacy of radiation therapy (RT) in the treatment of unresected keloids.

Clinical Trial Description

This will be a single-institution pilot study to evaluate the safety and efficacy of radiation therapy (RT) for the treatment of unresected keloids. The primary endpoint will be toxicity within 10 weeks of follow-up. Secondary endpoints will include cessation of growth or shrinkage of keloids, symptomatic response, and impact on quality of life. Primary Objective -evaluate feasibility and safety of radiation therapy only for the treatment of unresected keloids. Secondary Objectives: - To evaluate toxicity of RT for the treatment of unresected keloids. - To evaluate response of keloids, either stability or decrease in size, after primary RT. - To evaluate symptomatic response of unresected keloids to primary RT. - To assess the effect on quality of life of primary RT for unresected keloids After review of the literature on the use of RT for the treatment of keloids, both resected and unresected, as well as input of expert opinion and clinical experience by the study's radiation oncologists, the RT prescription dose for this study was selected to be 15 Gy, which will be divided into 5 Gy fractions delivered daily over on 3 consecutive days. Patients will receive RT using external beam radiotherapy (EBRT), delivered via either electrons or megavoltage photons, or brachytherapy; RT modality will be based on the judgment of the treating radiation oncologist. We estimate we will be able to recruit 15-20 patients in 6-12 months, thus we are aiming for a sample size of 15 patients. In successive intervals of enrollment and treatment of 5 patients (i.e. after 5, 10, and 15 patients have been enrolled), the study team will meet and perform interim analysis to evaluate the safety and efficacy of treatment. Investigators will discuss rates of toxicity and symptom management observed up to that point and determine if the study dose or protocol needs to be altered. Patients will be evaluated frequently for treatment-related toxicities using CTCAE v5.0 up to 1 year after completion of RT. Any adverse event will be considered by the study investigators to evaluate the safety of the protocol and to determine whether changes to the dosing regimen are required. ;

Related Conditions & MeSH terms

• Keloid

• NCT number: NCT04722263
• Study type: Interventional
• Source: Montefiore Medical Center
• Status: Active, not recruiting
• Phase: Early Phase 1
• Start date: December 1, 2020
• Completion date: December 2024